BRPI0410634A - processo - Google Patents

processo

Info

Publication number
BRPI0410634A
BRPI0410634A BRPI0410634-2A BRPI0410634A BRPI0410634A BR PI0410634 A BRPI0410634 A BR PI0410634A BR PI0410634 A BRPI0410634 A BR PI0410634A BR PI0410634 A BRPI0410634 A BR PI0410634A
Authority
BR
Brazil
Prior art keywords
genes
gene
gene set
nonresponders
responders
Prior art date
Application number
BRPI0410634-2A
Other languages
English (en)
Inventor
Takashi Tsuruo
Yusuke Nakamura
Saburo Sone
Masahiro Fukuoka
Original Assignee
Astrazeneca Uk Ltd
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312451A external-priority patent/GB0312451D0/en
Priority claimed from GB0322636A external-priority patent/GB0322636D0/en
Priority claimed from GB0327132A external-priority patent/GB0327132D0/en
Application filed by Astrazeneca Uk Ltd, Univ Tokyo filed Critical Astrazeneca Uk Ltd
Publication of BRPI0410634A publication Critical patent/BRPI0410634A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PROCESSO". A invenção diz respeito a um conjunto de genes marcadores isolados que compreende pelo menos um gene identificado com expressão diferencial entre pacientes que são respondedores e não respondedores a um inibidor do receptor tirosina quinase erbB; o dito conjunto de genes compreendendo um ou mais genes selecionados pelo menos do grupo que consiste dos (51) genes listados anexos incluindo oligonucleotídeos específicos do gene derivado dos ditos genes; e usos de tais conjuntos em aplicações de diagnóstico.
BRPI0410634-2A 2003-05-30 2004-06-01 processo BRPI0410634A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0312451A GB0312451D0 (en) 2003-05-30 2003-05-30 Process
GB0322636A GB0322636D0 (en) 2003-09-26 2003-09-26 Process
GB0327132A GB0327132D0 (en) 2003-11-21 2003-11-21 Process
PCT/GB2004/002316 WO2005049829A1 (en) 2003-05-30 2004-06-01 Process

Publications (1)

Publication Number Publication Date
BRPI0410634A true BRPI0410634A (pt) 2006-06-13

Family

ID=34623472

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410634-2A BRPI0410634A (pt) 2003-05-30 2004-06-01 processo

Country Status (12)

Country Link
US (1) US20060252056A1 (pt)
EP (2) EP2348110B1 (pt)
JP (2) JP4724657B2 (pt)
KR (1) KR101126560B1 (pt)
AU (1) AU2004291709C1 (pt)
BR (1) BRPI0410634A (pt)
CA (1) CA2527680A1 (pt)
IL (1) IL172029A (pt)
MX (1) MXPA05012939A (pt)
NO (1) NO20055459L (pt)
NZ (1) NZ543234A (pt)
WO (1) WO2005049829A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049829A1 (en) * 2003-05-30 2005-06-02 Astrazeneca Uk Limited Process
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
WO2007025044A2 (en) 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
JP2007135581A (ja) * 2005-10-20 2007-06-07 Japan Science & Technology Agency 自己免疫性血小板減少性紫斑病（ｉｔｐ）患者の血液細胞特異的遺伝子群
FI121236B (fi) * 2006-01-18 2010-08-31 Licentia Oy Menetelmä asbestialtistukseen liittyvien keuhkosyöpien tunnistamiseksi
US8138167B2 (en) 2006-02-10 2012-03-20 Oncotherapy Science, Inc. Methods for treating lung cancers
EP1988164A4 (en) * 2006-02-23 2009-04-22 Univ Kanazawa Nat Univ Corp METHOD FOR TESTING THE SENSITIVITY OF A SOLID TUMOR AGAINST TYROSINE KINASE INHIBITOR AND TEST KIT THEREFOR
WO2007101122A2 (en) * 2006-02-24 2007-09-07 University Of Chicago Methods and compositions involving slc17a1
WO2007123462A1 (en) 2006-04-25 2007-11-01 Shengyuan Xu A protein, an antibody and measurement of the protein
ES2539042T3 (es) 2006-06-02 2015-06-25 Glaxosmithkline Biologicals S.A. Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
WO2008064884A1 (en) * 2006-11-28 2008-06-05 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
KR20090087491A (ko) * 2006-12-04 2009-08-17 아보트 러보러터리즈 암 치료요법을 위한 동반 진단 검정
AU2008250033A1 (en) * 2007-05-11 2008-11-20 Enzon Pharmaceuticals, Inc. RNA antagonist compounds for the modulation of HER3
AU2008286337B2 (en) 2007-08-14 2011-10-27 F. Hoffmann-La Roche Ag Predictive marker for EGFR inhibitor treatment
CA2695070A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
JP2010535516A (ja) * 2007-08-14 2010-11-25 エフ．ホフマン−ラ ロシュ アーゲー Ｅｇｆｒ阻害剤治療のための予測マーカー
WO2009021679A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treamtent
JP5421260B2 (ja) * 2007-08-14 2014-02-19 エフ．ホフマン−ラ ロシュ アーゲー Ｅｇｆｒ阻害剤治療のための予測マーカー
MX2010001578A (es) * 2007-08-14 2010-03-15 Hoffmann La Roche Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
WO2009021682A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
KR20100037637A (ko) * 2007-08-14 2010-04-09 에프. 호프만-라 로슈 아게 Ｅｇｆｒ 억제제 치료에 대한 예측 마커
MX2010001580A (es) * 2007-08-14 2010-03-15 Hoffmann La Roche Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
KR20100044851A (ko) * 2007-08-14 2010-04-30 에프. 호프만-라 로슈 아게 Ｅｇｆｒ 억제제를 이용한 치료에 대한 예측 마커
WO2010015535A1 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
GB0904957D0 (en) * 2009-03-23 2009-05-06 Univ Erasmus Medical Ct Tumour gene profile
EP2239578A1 (en) * 2009-04-10 2010-10-13 PamGene B.V. Method for determining the survival prognosis of patients suffering from non-small cell lung cancer (NSCLC)
EP2419522A4 (en) * 2009-04-17 2012-10-31 Glen Weiss METHOD AND KITS FOR THE FORECASTING OF THERAPY RESULTS OF TYROSINE CHINESE INHIBITORS
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US20140249150A1 (en) * 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
TWI582239B (zh) * 2013-03-11 2017-05-11 諾華公司 與ｗｎｔ抑制劑相關之標記
EP3066474B1 (en) 2013-11-05 2019-04-03 Agency For Science, Technology And Research Bladder carcinoma biomarkers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
NZ508154A (en) 1998-04-29 2003-07-25 Osi Pharm Inc N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
CN1160338C (zh) 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂
JP2000287680A (ja) * 1999-04-09 2000-10-17 Sentan Kagaku Gijutsu Incubation Center:Kk 未成熟肝細胞を成熟肝細胞へ分化させる方法
JP2003504363A (ja) 1999-07-09 2003-02-04 グラクソ グループ リミテッド プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類
US7194269B2 (en) 2000-10-30 2007-03-20 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Industry Method and wireless communication hub for data communications
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
JP2005503145A (ja) * 2001-08-16 2005-02-03 ザ ユナイテッド ステイツ オブ アメリカ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 非小細胞肺癌の分子特性
JP2005531281A (ja) * 2001-11-02 2005-10-20 ファイザー・プロダクツ・インク 肺癌の治療および診断
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
WO2005049829A1 (en) * 2003-05-30 2005-06-02 Astrazeneca Uk Limited Process

Also Published As

Publication number Publication date
JP5217010B2 (ja) 2013-06-19
IL172029A (en) 2011-06-30
JP2006526420A (ja) 2006-11-24
MXPA05012939A (es) 2006-05-17
NZ543234A (en) 2009-04-30
NO20055459L (no) 2006-02-27
KR101126560B1 (ko) 2012-04-05
WO2005049829A1 (en) 2005-06-02
AU2004291709A1 (en) 2005-06-02
JP4724657B2 (ja) 2011-07-13
EP2348110A1 (en) 2011-07-27
EP1633870B1 (en) 2013-03-27
EP1633870A1 (en) 2006-03-15
KR20060002012A (ko) 2006-01-06
AU2004291709C1 (en) 2010-03-11
JP2011167188A (ja) 2011-09-01
US20060252056A1 (en) 2006-11-09
EP2348110B1 (en) 2013-03-27
NO20055459D0 (no) 2005-11-18
CA2527680A1 (en) 2005-06-02
AU2004291709B2 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
ATE167680T1 (de) Pteridin-nukleotidderivate als fluoreszierende sonden
Nardella et al. DNA methylation bisubstrate inhibitors are fast-acting drugs active against artemisinin-resistant Plasmodium falciparum parasites
DE69333073D1 (de) Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
WO2004035765A3 (en) Double-stranded rna structures and constructs, and methods for generating and using the same
WO2004011624A3 (en) Double stranded rna structures and constructs, and methods for generating and using the same
FR2722506B1 (fr) Composition contenant des acides nucleiques, preparation et utilisations
ATE416183T1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
GB2397818A (en) Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
EP1576145A4 (en) BIOINFORMATIVELY DETECTABLE GROUP OF NEW VIRAL REGULATORY GENES AND USES THEREOF
ES2105698T3 (es) Oligonucleotidos modificados con 7-deazapurina.
BR9913532A (pt) Novos inibidores heteroaromáticos de frutose 1,6-bifosfatase
BR0311814A (pt) Método de tratar câncer empregando inibidores de cinase
BRPI0414532A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente
IL185218A0 (en) Partly neutralised anionic (meth) acrylate copolymer
NO20055459L (no) Prosesser
WO2004078941A3 (en) Modulation of gene expression using dna-rna hybrids
DK1397681T3 (da) Fremgangsmåde til identificering af midler til behandling af diabetes
DE69815370D1 (de) Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
Hawkins et al. Multiple origins of resistance-conferring mutations in Plasmodium vivax dihydrofolate reductase
BR0312944A (pt) Oligonucleotìdeos para detecção de microorganismos
Zalloum et al. Trypanosoma cruzi: two genetic groups in Paraná State, Southern Brazil
Telleria et al. Predominant clonal evolution leads to a close parity between gene expression profiles and subspecific phylogeny in Trypanosoma cruzi
EP1248635A4 (en) ANTISENSE MODULATION OF THE GLYCOGEN SYNTHASE-KINASE-3ALPHA EXPRESSION
Wurtz et al. Phenotypic and transcriptomic analyses of Plasmodium falciparum protein kinase A catalytic subunit inhibition

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.